Neonatal hypoglycaemia is associated with adverse later development, particularly visuo-motor and executive function impairment. As neonatal hypoglycaemia is common and frequently asymptomatic in at-risk babies, these babies are screened for hypoglycaemia in the first 1-2 days after birth with frequent blood glucose measurements. Neonatal hypoglycaemia can be prevented and treated with buccal dextrose gel, and it is also common to treat hypoglycaemic babies with formula and intravenous dextrose. However, it is uncertain if screening, prophylaxis or treatment improves long-term outcomes of babies at risk of neonatal hypoglycaemia. This presentation will assess the latest evidence for screening, prophylaxis and treatment of babies at risk to improve long-term neurodevelopmental outcomes.